Vor Biopharma shares surge 10.16% intraday after Telitacicept meets primary endpoint in Phase 3 IgA Nephropathy trial.

Vor Biopharma surged 10.16% intraday following the release of positive Phase 3 clinical trial data for Telitacicept in IgA Nephropathy on November 8, 2025, and a subsequent corporate update on November 14, 2025. The trial demonstrated the drug’s efficacy in reducing proteinuria, a key indicator of kidney disease progression, reinforcing investor confidence in the company’s pipeline. Additionally, the November 14 update highlighted strategic progress, likely including advancements in regulatory or commercialization efforts, which aligned with the stock’s upward momentum. While a $100 million public offering on November 10 initially pressured shares, the intraday rally suggests renewed optimism driven by clinical validation and operational updates.